[Hypomagnesemia induced by gastrointestinal losses due to carfilzomib].
Rinsho Ketsueki
; 62(3): 190-192, 2021.
Article
em Ja
| MEDLINE
| ID: mdl-33828013
ABSTRACT
A 67-year-old man with multiple myeloma had been treated with carfilzomib, lenalidomide, and dexamethasone (KRd) therapy. During the second course, he developed dyspnea, which gradually worsened. After admission, gastrointestinal losses of magnesium were confirmed, and intravenous magnesium was administered, which consequently improved his symptoms. Although KRd therapy was resumed, hypomagnesemia was recurring. Therefore, carfilzomib was replaced with ixazomib, which improved the patient's hypomagnesemia. The major causes of hypomagnesemia are gastrointestinal and renal losses; our case appeared to have gastrointestinal losses of magnesium and was successfully treated by discontinuing carfilzomib. Hypomagnesemia should be considered in patients receiving carfilzomib; furthermore, clinicians should consider discontinuing carfilzomib as its treatment.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Magnésio
/
Mieloma Múltiplo
Limite:
Aged
/
Humans
/
Male
Idioma:
Ja
Revista:
Rinsho Ketsueki
Ano de publicação:
2021
Tipo de documento:
Article